1. Generics Bulletin

Sun Sees New Prescriptions Drought Amid COVID-19

But Situation Improving And Ilumya Solid

 
• By Anju Ghangurde

Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

Prescription
Sun expects a challenging Q1 across pharma in India • Source: Shutterstock

Sun Pharmaceutical Industries’ earnings call for the fourth quarter of fiscal 2020 provided a glimpse of the challenging environment that the Indian firm, like the rest of the industry, was operating in amid COVID-19, both on home turf and in the US.

While a significant proportion of physicians stayed away from their clinics in India and sales personnel were initially grounded amid the local lock-down and product ramp-ups and doctor calls were impacted in Q4 in the US as well,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business